No revenue, vague proxy, no product to market, past history of incomplete programs (myobalst), very poor PR, missed deadlines, history of pps dilution, hedge fund manager acting as a CEO, no insider buying only selling and careless attitude about shareholders investment.
No large investors or funds will invest IMO.